See What HealthDay Can Do For You
Contact Us

Opioid-Related Constipation Tx Suboptimal in Pregnancy

PAMORA strategy appears to safe with superior effectiveness

pregnancy

TUESDAY, Dec. 15, 2015 (HealthDay News) -- Conventional non-pharmacologic and pharmacologic options for the management of opioid-induced constipation (OIC) in pregnancy are often ineffective or cause potentially troublesome adverse effects, according to a study published in the December issue of the Journal of Clinical Pharmacy and Therapeutics.

Z. Li, Pharm.D., from Temple University in Philadelphia, and colleagues conducted a literature review of the non-pharmacologic (dietary modifications, laxatives, and peripherally acting mu-opioid receptor antagonists [PAMORAs]) and pharmacologic treatment options for the management of OIC during pregnancy.

The researchers found that while generally safe, non-pharmacologic approaches are usually insufficient when used alone to control OIC in pregnancy. Bulking, osmotic, and stimulant laxatives can be effective, but have potential adverse effects (electrolyte disturbances, dehydration, abdominal pain, and pulmonary edema or hypermagnesemia in the extreme) that might be particularly troublesome during pregnancy. Only minimal side effects have been seen with PAMORAs, which lessen OIC without affecting opioid-induced analgesia.

"The PAMORA strategy appears to provide a safe and effective new option superior to conventional therapies for the management of OIC during pregnancy," the authors write.

Abstract
Full Text

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.